- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02751021
Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction (SAPAAD)
Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction: SAPAAD Study
Little is known about potential relationships between sleep apnea, plasma aldosterone and diastolic dysfunction which is a very frequent finding among patients requiring permanent cardiac pacing. Sleep apnea is often under diagnosed by clinical examination. Confirmation tests are expensive and access is limited. A specific algorithm available in a recent pacemaker allows assessing breathing variations using minute ventilation sensor, with a good agreement between the respiratory disturbance index and polysomnography results for the diagnosis of severe sleep apnea.
The purpose of the study is to examine the diagnostic accuracy of a new pacemaker algorithm for the diagnosis of obstructive sleep apnea in patients presenting with diastolic dysfunction. The investigators also aim to highlight a correlation between plasma aldosterone levels and the severity of sleep apnea, with a reversal effect of ventilation therapy in this specific population.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Normandy
-
Caen, Normandy, France, 14000
- Caen University hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- indication for permanent cardiac pacing (third degree atrioventricular block, second degree atrioventricular block mobitz 2 type, symptomatic sinus node dysfunction including brady-tachy form of sick sinus syndrome or bradyarrhythmia)
- Diastolic dysfunction diagnosed at the transthoracic echocardiography
Exclusion Criteria:
- younger than 18 years old
- lack of informed consent form
- impossibility to fit in the scheduled study plan
- indication for cardiac resynchronization or left ventricular ejection fraction lower than 45%
- indication for epicardial pacemaker, known severe sleep apnea treated by continuous positive airway pressure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Sleep apnea diagnosis
The intervention is the use of the pacemaker diagnostic algorithm named Sleep Apnea Monitoring to detect sleep apnea and the attended cardiorespiratory sleep study to confirm the diagnostic.
|
evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea
sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison between respiratory disturbance index recorded the sleep study night and Apnea hypopnea index
Time Frame: 2 months after pacemaker implantation
|
number of apneas and hypopneas per hour (5 hours recorded by night) evaluated by the pacemaker algorithm during the night of the attended cardiorespiratory sleep study compared to the apnea hypopnea index evaluated by the portable monitor during the attended cardiorespiratory sleep study
|
2 months after pacemaker implantation
|
|
Comparison between the mean respiratory disturbance index of the last month and Apnea hypopnea index
Time Frame: 2 months after pacemaker implantation
|
Average value of respiratory disturbance index recorded each night during the last month compared to the apnea hypopnea index evaluated by the portable monitor during the attended cardiorespiratory sleep study
|
2 months after pacemaker implantation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measurement of plasmatic aldosterone and correlation with apnea hypopnea index
Time Frame: 2 months after pacemaker implantation and one month after the beginning of continuous positive airway pressure (CPAP) therapy in apneic patients
|
2 months after pacemaker implantation and one month after the beginning of continuous positive airway pressure (CPAP) therapy in apneic patients
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Laure CHAMP-RIGOT, MD, University Hospital, Caen
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Nervous System Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Heart Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Sleep Wake Disorders
- Apnea
- Sleep Disorders, Intrinsic
- Dyssomnias
- Adrenal Gland Diseases
- Adrenocortical Hyperfunction
- Pathological Conditions, Signs and Symptoms
- Sleep Apnea Syndromes
- Arrhythmias, Cardiac
- Hyperaldosteronism
Other Study ID Numbers
- 2016-A00034-47
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.